Analysts expect VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) to post earnings of ($0.08) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for VBI Vaccines’ earnings. VBI Vaccines reported earnings of ($0.07) per share during the same quarter last year, which indicates a negative year over year growth rate of 14.3%. The business is scheduled to announce its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that VBI Vaccines will report full year earnings of ($0.31) per share for the current year, with EPS estimates ranging from ($0.34) to ($0.29). For the next financial year, analysts forecast that the firm will report earnings of ($0.24) per share, with EPS estimates ranging from ($0.29) to ($0.16). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow VBI Vaccines.
VBI Vaccines (NASDAQ:VBIV – Get Rating) last issued its quarterly earnings data on Monday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.07). VBI Vaccines had a negative net margin of 11,054.36% and a negative return on equity of 42.79%. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.14 million.
NASDAQ:VBIV opened at $1.35 on Monday. The company has a quick ratio of 3.92, a current ratio of 4.00 and a debt-to-equity ratio of 0.20. The firm has a market cap of $347.36 million, a P/E ratio of -5.00 and a beta of 1.97. The business’s 50-day moving average price is $1.53 and its 200 day moving average price is $2.13. VBI Vaccines has a 52-week low of $1.21 and a 52-week high of $4.31.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Walleye Capital LLC increased its holdings in VBI Vaccines by 48.2% during the 4th quarter. Walleye Capital LLC now owns 27,011 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 8,783 shares during the period. BlackRock Inc. grew its stake in shares of VBI Vaccines by 3.6% in the fourth quarter. BlackRock Inc. now owns 13,269,221 shares of the biopharmaceutical company’s stock worth $31,049,000 after acquiring an additional 462,785 shares during the last quarter. Wells Fargo & Company MN raised its holdings in VBI Vaccines by 1,934.7% in the 4th quarter. Wells Fargo & Company MN now owns 113,697 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 108,109 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of VBI Vaccines by 243.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,153,567 shares of the biopharmaceutical company’s stock valued at $2,699,000 after buying an additional 818,173 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of VBI Vaccines during the 4th quarter valued at about $126,000. Institutional investors and hedge funds own 43.61% of the company’s stock.
About VBI Vaccines (Get Rating)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.